The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

NMDA receptors are present throughout the brain and are essential for maintaining consciousness. For this reason, she ...

Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology ...

There are now ketamine clinics nationwide where the drug is given intravenously to treat depression. Like a lock and key, ketamine binds to the brain via N-methyl-D-aspartate (NMDA) receptors.

Drug Discov. 7 426–437; 2008). Increased levels of glutamate have been found in the frontal cortex of patients with MDD, and the non-selective NMDA receptor antagonist ketamine has shown ...

despite safety concerns arising from the fact that the anesthetic is commonly abused as a recreational drug. It works on the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment ...

NMDA antagonist dextromethorphan is an ingredient ... than current tricyclic or selective serotonin reuptake inhibitor drugs can take weeks to elevate mood, placing severely affected patients ...

a medication that crosses the blood-brain barrier to target NMDA receptors. Dextromethorphan is commonly used in cough drugs; its targeting and blocking of NMDA receptors suppresses activity in ...

Pregnancy. Nursing mothers. Caution with other NMDA antagonists (eg, amantadine, ketamine, dextromethorphan). May affect or be affected by renally-excreted drugs (eg, triamterene, HCTZ ...